These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 16288878)

  • 41. Design and synthesis of novel 2,3-dihydro-1H-isoindoles with high affinity and selectivity for the dopamine D3 receptor.
    Austin NE; Avenell KY; Boyfield I; Branch CL; Hadley MS; Jeffrey P; Johnson CN; Macdonald GJ; Nash DJ; Riley GJ; Smith AB; Stemp G; Thewlis KM; Vong AK; Wood MD
    Bioorg Med Chem Lett; 2001 Mar; 11(5):685-8. PubMed ID: 11266169
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacological characterization of mammalian D1 and D2 dopamine receptors expressed in Drosophila Schneider-2 cells.
    Schetz JA; Kim OJ; Sibley DR
    J Recept Signal Transduct Res; 2003 Feb; 23(1):99-109. PubMed ID: 12680592
    [TBL] [Abstract][Full Text] [Related]  

  • 43. 2-[4-(3,4-Dimethylphenyl)piperazin-1-ylmethyl]-1H benzoimidazole (A-381393), a selective dopamine D4 receptor antagonist.
    Nakane M; Cowart MD; Hsieh GC; Miller L; Uchic ME; Chang R; Terranova MA; Donnelly-Roberts DL; Namovic MT; Miller TR; Wetter JM; Marsh K; Stewart AO; Brioni JD; Moreland RB
    Neuropharmacology; 2005 Jul; 49(1):112-21. PubMed ID: 15992586
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [3H]-quinelorane binds to D2 and D3 dopamine receptors in the rat brain.
    Gackenheimer SL; Schaus JM; Gehlert DR
    J Pharmacol Exp Ther; 1995 Sep; 274(3):1558-65. PubMed ID: 7562534
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Novel benzopyrano[3,4-c]pyrrole derivatives as potent and selective dopamine D3 receptor antagonist.
    Dubuffet T; Newman-Tancredi A; Cussac D; Audinot V; Loutz A; Millan MJ; Lavielle G
    Bioorg Med Chem Lett; 1999 Jul; 9(14):2059-64. PubMed ID: 10450981
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluation of the effects of the enantiomers of reduced haloperidol, azaperol, and related 4-amino-1-arylbutanols on dopamine and sigma receptors.
    Jaen JC; Caprathe BW; Pugsley TA; Wise LD; Akunne H
    J Med Chem; 1993 Nov; 36(24):3929-36. PubMed ID: 7902870
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The agonist activities of the putative antipsychotic agents, L-745,870 and U-101958 in HEK293 cells expressing the human dopamine D4.4 receptor.
    Gazi L; Bobirnac I; Danzeisen M; Schüpbach E; Bruinvels AT; Geisse S; Sommer B; Hoyer D; Tricklebank M; Schoeffter P
    Br J Pharmacol; 1998 Jul; 124(5):889-96. PubMed ID: 9692773
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Synthesis, pharmacological evaluation and molecular modeling studies of triazole containing dopamine D3 receptor ligands.
    Peng X; Wang Q; Mishra Y; Xu J; Reichert DE; Malik M; Taylor M; Luedtke RR; Mach RH
    Bioorg Med Chem Lett; 2015 Feb; 25(3):519-23. PubMed ID: 25556097
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dopamine agonist-induced yawning in rats: a dopamine D3 receptor-mediated behavior.
    Collins GT; Witkin JM; Newman AH; Svensson KA; Grundt P; Cao J; Woods JH
    J Pharmacol Exp Ther; 2005 Jul; 314(1):310-9. PubMed ID: 15833897
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacological actions of a novel, high-affinity, and selective human dopamine D(3) receptor antagonist, SB-277011-A.
    Reavill C; Taylor SG; Wood MD; Ashmeade T; Austin NE; Avenell KY; Boyfield I; Branch CL; Cilia J; Coldwell MC; Hadley MS; Hunter AJ; Jeffrey P; Jewitt F; Johnson CN; Jones DN; Medhurst AD; Middlemiss DN; Nash DJ; Riley GJ; Routledge C; Stemp G; Thewlis KM; Trail B; Vong AK; Hagan JJ
    J Pharmacol Exp Ther; 2000 Sep; 294(3):1154-65. PubMed ID: 10945872
    [TBL] [Abstract][Full Text] [Related]  

  • 51. SPECT tracer [(123)I]IBZM has similar affinity to dopamine D2 and D3 receptors.
    Videbaek C; Toska K; Scheideler MA; Paulson OB; Moos Knudsen G
    Synapse; 2000 Dec; 38(3):338-42. PubMed ID: 11020237
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Selective inhibition of adenylyl cyclase type V by the dopamine D3 receptor.
    Robinson SW; Caron MG
    Mol Pharmacol; 1997 Sep; 52(3):508-14. PubMed ID: 9281614
    [TBL] [Abstract][Full Text] [Related]  

  • 53. An interactive SAR approach to discover novel hybrid thieno probes as ligands for D2-like receptors with affinities in the subnanomolar range.
    Abdel-Fattah MA; Lehmann J; Abadi AH
    Chem Biodivers; 2013 Dec; 10(12):2247-66. PubMed ID: 24327445
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The human dopamine D2(Longer) receptor has a high-affinity state and inhibits adenylyl cyclase.
    Liu IS; George SR; Seeman P
    Brain Res Mol Brain Res; 2000 May; 77(2):281-4. PubMed ID: 10837924
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The human D2 dopamine receptor synergizes with the A2A adenosine receptor to stimulate adenylyl cyclase in PC12 cells.
    Kudlacek O; Just H; Korkhov VM; Vartian N; Klinger M; Pankevych H; Yang Q; Nanoff C; Freissmuth M; Boehm S
    Neuropsychopharmacology; 2003 Jul; 28(7):1317-27. PubMed ID: 12784121
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of the functional potencies of ropinirole and other dopamine receptor agonists at human D2(long), D3 and D4.4 receptors expressed in Chinese hamster ovary cells.
    Coldwell MC; Boyfield I; Brown T; Hagan JJ; Middlemiss DN
    Br J Pharmacol; 1999 Aug; 127(7):1696-702. PubMed ID: 10455328
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Activation of heterologously expressed D3 dopamine receptors: comparison with D2 dopamine receptors.
    Chio CL; Lajiness ME; Huff RM
    Mol Pharmacol; 1994 Jan; 45(1):51-60. PubMed ID: 8302280
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release.
    Cosi C; Carilla-Durand E; Assié MB; Ormiere AM; Maraval M; Leduc N; Newman-Tancredi A
    Eur J Pharmacol; 2006 Mar; 535(1-3):135-44. PubMed ID: 16554049
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The novel antidyskinetic drug sarizotan elicits different functional responses at human D2-like dopamine receptors.
    Kuzhikandathil EV; Bartoszyk GD
    Neuropharmacology; 2006 Sep; 51(4):873-84. PubMed ID: 16844149
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Lack of discrimination by agonists for D2 and D3 dopamine receptors.
    Burris KD; Pacheco MA; Filtz TM; Kung MP; Kung HF; Molinoff PB
    Neuropsychopharmacology; 1995 Jul; 12(4):335-45. PubMed ID: 7576010
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.